What is it about?
Hemodialysis patients have an extremely high cardiovascular mortality. Fibroblast-growth factor (FGF)23 is a toxic compound raised during kidney disease and is positively associated with patients mortality. Klotho, a recently discoverd protein with cardioprotective properties, is decreased during kidney failure.
Featured Image
Why is it important?
We make the assumption that Klotho may counteract the cardiotoxic effects of FGF23; CKD patients with elevated FGF23 may undergo protection if they have enough klotho, and those with reduced circulating klotho may be those who will die from FGF23 toxicity. THerefore when studying cardivascular status and survival in chronic kidney disease patients and particularly thiose undergoing dialysis, Kltho should be added to the explanatory armentarium regarding survival.
Perspectives
Serum Koltho should be systematically reported in cardiovascular studeis in CKD patients.
denis fouque
Universite Claude Bernard Lyon 1
Read the Original
This page is a summary of: Fibroblast Growth Factor-23 Is Not a Single Bystander in Chronic Kidney Disease Mortality, Journal of the American Society of Nephrology, July 2018, American Society of Nephrology,
DOI: 10.1681/asn.2018060583.
You can read the full text:
Contributors
The following have contributed to this page
